COVID-19-Associated Mucormycosis: Identifying Mortality Predictors in a Retrospective Cohort Study - Takeaways - MDSpire

COVID-19-Associated Mucormycosis: Identifying Mortality Predictors in a Retrospective Cohort Study

  • By

  • Zahra Ghavami

  • Mahboubeh Haddad

  • Fereshte Sheybani

  • Matin Shirazinia

  • Maliheh Dadgar Moghadam

  • November 3, 2025

  • 0 min

Share

  • 1

    COVID-19-associated mucormycosis (CAM) is a serious complication exacerbated by immunosuppressive treatments, particularly corticosteroids.

  • 2

    In a study of 81 patients, 76.5% had diabetes mellitus, and 90.1% received corticosteroids, highlighting the risk factors for CAM.

  • 3

    One-month survival for CAM patients was 61.7%, decreasing to 51.9% at three months, indicating high mortality rates.

  • 4

    Elevated CRP levels were significantly associated with increased mortality, while longer antifungal treatment duration reduced mortality.

  • 5

    Palatal necrosis was identified as a risk factor for mortality, whereas the use of posaconazole was linked to lower mortality rates.

Original Source(s)

COVID-19-Associated Mucormycosis: Identifying Mortality Predictors in a Retrospective Cohort Study

  • by Zahra Ghavami, Mahboubeh Haddad, Fereshte Sheybani, Matin Shirazinia, Maliheh Dadgar Moghadam

  • November 3, 2025

Related Content

Makary Resigns as FDA Commissioner Following Policy Disputes

Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization

Early-Phase Oral Antiviral Use and Post–COVID-19 Condition in Outpatients

Beyond recovery: long-term cardiovascular risks after severe COVID-19 requiring intensive care